Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection

Stock Information for Finch Therapeutics Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Finch Therapeutics Group Inc.

Finch Announces Delisting from Nasdaq and SEC Deregistration
Finch Announces Reverse Stock Split of Common Stock
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
Finch Therapeutics Announces Executive Leadership Transitions
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.